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Abstract 
Dysregulation 
differentiation is 
of hematopoietic ellular differentiation contributes to leukemogenesis. Unfortunately, relatively little is known about how cell 
regulated. Considering that heat shock proteins (hsp) and specifically the small hsps have been increasingly linked to growth 
regulation, we sought to determine whether the mammalian small hsp (hsp28) is a growth-regulatory candidate during hematopoietic ell differen- 
tiation. Because of its effects on cell growth and differentiation and its increasing clinical use as a differentiating agent, we examined the effect of 
retinoic acid (RA) on hsp28 during differentiation of the human leukemic HL-60 cell line. Although hsp28 was constitutively expressed at low levels 
in untreated HL-60 cells, steady state hsp28 protein increased transiently, concomitant with the onset of Gl cell cycle arrest. Furthermore, hsp28 
phosphorylation transiently increased within one hour following treatment with RA. Interestingly, in contrast to other differentiating agents the 
induction of hsp28 by RA was post-transcriptionally mediated with hsp28 protein and mRNA being discordantly regulated. These observations 
underscore the complex regulation of hsp28 by RA during granulocytic differentiation of human leukemic ells and indicate hsp28 as an intermediary 
in the pathway through which retinoids exert their growth and differentiative ffects. 
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1. Introduction 
Differentiation is a fundamental cellular program 
which limits the clonal expansion of hematopoietic ell 
populations since in general, differentiation and cell 
growth are mutually exclusive. The importance of this 
process is highlighted by the fact that its dysregulation 
contributes to leukemogenesis [ 11. Unfortunately, rela- 
tively little is known about how cell differentiation is 
regulated. One of the prototypic models used to study 
this process is the promyelocytic leukemic HL-60 cell 
line, which represents cells arrested at the promyelocytic 
stage of myleoid development. The block in development 
is reversible however, since these cells undergo either 
granulocytic of monocytic maturation in response to a 
number of exogenous agents [2]. HL-60 cells have there- 
fore been used to study the role of proto-oncogenes as 
well as other growth-regulatory molecules during hema- 
topoietic differentiation. Interestingly, the small mam- 
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malian heat shock proteins (hsp28) was identified as a 
novel marker of growth arrest during phorbol ester-in- 
duced monocytic differentiation of HL-60 cells. Changes 
in hsp28 protein expression and phosphorylation state 
mark the onset of Gl cell cycle arrest during monocytic 
differentiation [3,4]. Similar changes in hsp28 protein 
expression have also been observed in differentiating 
human B lymphocytes and in phorbol ester-induced 
growth arrest of lymphoma cell lines [5]. These mam- 
malian studies extend those in Drosophila where the con- 
stitutive expression of the small hsps during development 
suggests amultifactorial role for these proteins in growth 
regulation [6-lo]. Importantly, a direct link between 
small hsps and growth regulation was recently demon- 
strated in a murine tumor model where overexpression 
of the murine low molecular hsp (hsp25) led to growth 
inhibition [ 1 I]. 
In the current study we examine the regulation of 
hsp28 during retinoic acid-induced granulocytic differen- 
tiation of HL-60 cells. RA was particularly interesting 
because of its effects on cell growth and differentiation 
in vitro as well as its increasing clinical use as a differen- 
tiating agent in the treatment of human malignancies 
[12-141. We now show that RA has significant effects on 
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hsp28 protein expression and phosphorylation. These 
changes are temporally associated with down-regulation 
of cell growth and the onset of Gl cell cycle arrest and 
are reminiscent of those changes observed following 
PMA-induced monocytic differentiation of HL-60 cells 
[3,4]. However, in contrast to PMA, RA-mediated induc- 
tion of hsp28 protein appears to be regulated at the 
post-transcriptional level. 
2. Materials and methods 
2.1. Cell Culture 
HL-60 cells were obtained from the American Type Culture Collec- 
tion and cultured in RPM1 1640 (Gibco Laboratories, Grand Island, 
NY) supplemented with 10% heat inactivated FCS, 2 mM glutamine, 
1 mM sodium pyruvate, and 5 &ml gentamycin in tissue flasks (Cor- 
ning Glass Works, Coming, NY). 
2.2. Induction of terminal differentiation 
HL-60 cells were maintained at logarithmic growth phase at 3 x 10’ 
cells/ml. To induce granulocytic differentiation, cells were treated with 
all-trans-retinoic acid (Sigma, St. Louis, MO) at a final concentration 
of 1 PM. At various time points prior to and following treatment with 
RA, Wright-Giemsa stains were obtained on cytosmears. 
2.3. Radiolabeling and immunoprecipitations 
HL-60 treated or not with RA were incubated for 30 min at 37°C 
in RPM1 1640 lacking phosphate before being exposed to 0.25 mCi/ml 
[32P]orthophosphate (carrier free; Amersham, UK) in the same me- 
dium. Labeling was for 30 min. The labeling medium was then removed 
and the cells were quickly washed in ice-cold phosphate-buffered saline 
(PBS) and harvested. Equal amount of protein from labeled cell lysates 
were immunoprecipitated with anti-hsp28 antibody as previously de- 
scribed [3,15]. 
2.4. One and two-dimensional gel electrophoresis and immunoblot analysis 
Gel electrophoresis and immunoblotting were performed as previ- 
ously described [3,16]. Purified hsp28 was from StressGen Corp. (Victo- 
ria, Canada). For 2D immunoblots, 1 x 10’ cells were used. Im- 
munoblots were probed with anti-hsp28 antibody [ 161 and developed 
with the ECL-kit from Amersham (UK). 
2.5. Preparation of RNA and Northern blot analysis 
Total cellular RNA was purified by the guanidium thiocyanate/CsCl 
method [17]. Intactness of RNA was verified by ethidium bromide 
staining (data not shown). Equal amounts (20 pg) of RNA were run 
on a 1.3% agarose gel and transferred onto a Zeta-Probe membrane 
(Bio-Rad Laboratories, Richmond, CA). Hybridization was performed 
using a “P-labeled cDNA probe from the human hsp28 gene 
(StressGen Corp., Victoria, Canada) [18]. To control for equal loading 
of RNA, blots were hybridized with a “P-labeled,&actin cDNA probe. 
2.6. Cellular proliferation and cell cycle analysis 
Microcultures were pulsed with 1 PCi [3H]thymidine (Amersham, 
Arlington Heights, IL) for 4 h. Dried filters were counted on a Packard 
Tri-carb scintillation counter (Packard, Downers Grove, IL). The stim- 
ulation index (S.I.) represents the following: S.I. = sample (cpm)/blank 
(cpm). 1 x lo6 cells were harvested at various time points following 
treatment with RA. Cells were processed with the Coulter DNA-Prep 
reagent (Coulter Immunology, Hialeah, FL) and examined by flow 
cytometric analysis as described by the manufacturer. 
3. Results 
3.1. Increased hsp28 steady-state protein expression in 
differentiating HL-60 cells 
Hsp28 steady-state protein expression was examined 
by immunoblot analysis at various time points prior to 
and following treatment of HL-60 cells with RA (1 PM). 
In order to control for differentiation-induced changes 
in cell size and protein content, equal amounts of total 
cellular protein (50 pug) were loaded at each time point. 
As shown in Fig. la, hsp28 was constitutively expressed 
in untreated cells. Twenty-four hours following treat- 
ment with RA, hsp28 steady-state protein had signifi- 
cantly increased. Similar to both monocytic differentia- 
tion of HL-60 cell [3] and differentiating B lymphocytes 
[5], increased hsp28 protein was transient, returning to 
baseline levels by 48 and 72 h (Fig. la). As a control, 
purified hsp28 was also immunoblotted (Fig. la, lane 
Ctl). 
Historically, changes in cell morphology have been 
used to follow the progression of myelomonocytic differ- 
entiationc. Granulocytic differentiation of HL-60 cells 
is marked by a decrease in the nuclear:cytoplasmic ratio, 
condensation of nucleoplasm, and loss of multiple nucle- 
oli. In response to RA, HL-60 cells differentiate to a 
more mature metamyelocyte or band form. In Fig. lb, 
HL-60 cells prior to and at 24 and 72 h following treat- 
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Fig. 1. Transient increase in hsp28 steady-state protein expression ac- 
companies growth arrest of HL-60 cells treated with RA. (a) Hsp28 
steady-state protein expression was examined by immunoblot analysis * 
at various time points prior to and following treatment with RA (1 PM). 
At each time point, equal amounts of total cellular protein (5Opg) were 
separated by 12% SDS-polyacrylamide gel electrophoresis. Proteins 
were transferred to nitrocellulose and immunoblotted using a polyclo- 
nal anti-hsp28 primary antibody. Protein signal was detecte$using a 
secondary alkaline phosphatase-conjugated goat anti-rabbit antibody. 
As a control, purified hsp28 was immunoblotted (lane Ctl). The corre- 
sponding level of cellular proliferation (% of control thymidine incorpo- 
ration) is shown below each time point. Cells were incubated with 1 pCi 
[‘Hlthymidine for 4 h. (b) Wright-Giemsa stain of HL-60 cytosmear at 
0, 24 and 72 h following treatment with RA. (c) Ce&&ycle analysis at 
various time points prior to and following treatment with RA. Corre- 
sponding peaks for Gl and S phase are indicated. 
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ment with RA were examined by Wright-Giemsa stain. 
In our hands, less than 1% of untreated HL-60 cells 
exhibited morphologic features characteristic of mature 
metamyelocytes or bands. Although there was gradation 
of differentiative changes at each time point, significant 
maturation was not observed until 48 to 72 h, at which 
time at least 75% of cells exhibited characteristic features 
of metamyelocytes or bands (condensed/intended nu- 
cleus, and loss of multiple nucleoli) (Fig. 1 b). In addition 
at these morphologic changes, the expression of granulo- 
cytic differentiative cell surface markers (i.e. CD1 1 b) did 
not significantly increase until approximately 72 h after 
RA (data not shown). Growth inhibition and cell cycle 
growth arrest preceded morphologic differentiation. As 
shown, [3H]thymidine incorporation decreased 35% 
twenty-four hours after exposure to RA, with continued 
growth-inhibition at 48 and 72 h (70% inhibition) (Fig. 
la). Decreased [3H]thymidine incorporation was associ- 
ated with the onset of Gl cell cycle arrest. As shown in 
Fig. lc, the decrease in the percentage of cells in S phase 
during the first 24 h following treatment with RA was 
associated with a concomitant increase in the percentage 
of cells blocked in Gl. Therefore, peak hsp28 protein 
expression occurred concomitant with decreased 
[3H]thymidine incorporation and the onset of Gl cell 
cycle arrest. 
3.2. Stimulation of hsp28 phosphorylation i  response to 
RA 
The small hsps are rapidly phosphorylated in response 
to heat shock and display an accumulation of 
phosphorylated isoforms as seen in 2D immunoblots 
analysis ([ 16,201 and Fig. 2). The most basic isoform (‘a’) 
represents the unphosphorylated form of the protein 
while the more acidic isoforms (‘b’ and ‘c’) are 
phosphorylated. Therefore, one can assess hsp28 phos- 
phorylation state through the relative expression of its 
isoforms. To this end, 2D immunoblotting was per- 
formed on HL-60 cell lysates prepared at various time 
points prior to and following treatment with RA (Fig. 
2A). In control (untreated) cells, isoform ‘a’ predomi- 
nated. However, within 1 h following treatment with RA, 
isoform ‘b’ increased significantly and isoform ‘c’ was 
now detectable. Increased expression of the 
phosphorylated isoforms was transient, with the steady 
state levels of the ‘b’ isoform returning to baseline by 17 
h. This isoform was no longer detectable by 45 h. 2D gel 
analysis of immunoprecipitated hsp28 isoforms from 
cells labeled for 1 h with [32P]orthophosphate was also 
performed prior to and after RA addition. As seen in 
Fig. 2B an increased phosphorylation of the ‘b’ and ‘c’ 
isoforpls is observed during the first hour of RA treat- 
ment. 17 h after RA addition, the pattern of hsp28 phos- 
phoryl&on resembled that observed in untreated cells. 
By 45”h the protein was dephosphorylated (not 
shown). 
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Fig. 2. Retinoic acid induced granulocytic differentiation modulates 
hsp28 phosphorylation. (A) Analysis of hsp28 isoforms by 2D im- 
munoblotting. The profile of hsp28 isoforms at various time points 
prior to (0) and at 1 h, 17 h and 45 h (indicated 1, 17 and 45 in the figure) 
following treatment with RA (1 PM) was determined by 2D im- 
munoblot analysis. At each time point, cells were harvested, lysed in 
Laemmli sample buffer and then analyzed in 2D immunoblots probed 
with anti hsp28 antibody as described in Section 2. The blots were 
developed and visualized using the ECL detection method. The pattern 
of hsp28 isoforms following exposure to a heat shock treatment for 1 
h at 43°C is indicated (HS). (B) 2D gel analysis of immunoprecipitated 
hsp28 isoforms from cells labeled for one hour with [‘*P]ortho- 
phosphate ither prior to (0) and during the first (1) and the seventieth 
(17) hour following RA treatment. Acidic end is to the left. Only the 
portion of the autoradiographs howing hsp28 isoforms is presented. 
The unphosphorylated hsp28 isoform is indicated (a) as well the 
phospho-isoforms (b and c). Note the transient increased phosphoryla- 
tion of hsp28 following RA treatment which resembles that observed 
after heat shock treatment. 
3.3. Increased hsp28 steady-state protein in response to 
RA is post-transcriptionally mediated 
Total cellular RNA was isolated from HL-60 cells at 
various time points prior to and following treatment with 
RA. Equal amounts of RNA were separated by North- 
ern blotting and hybridized with a 32P-labeled hsp28 
cDNA probe. In contrast to hsp28 protein, correspond- 
ing hsp28 steady-state mRNA levels rapidly decreased in 
response to RA (Fig. 3, top panel). By 24 h, hsp28 
steady-state message was barely detectable. Equal load- 
ing and intactness of RNA was verified by re-hybridizing 
with a 32P-labeled /I-actin probe (Fig. 3, lower panel). 
4. Discussion 
The rationale for using retinoic acid as a treatment for 
promyelocytic leukemia stems from its ability to induce 
these developmentally arrested leukemic cells to undergo 
terminal differentiation [2&22]. Very little is currently 
known about the molecules involved in mediating the 
growth and differentiative ffects of RA. Considering the 
increasing role that small hsps play in growth regulation, 
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Fig. 3. Down-regulation of hsp28 steady-state mRNA in response to 
RA. Total cellular RNA was extracted from HL-60 cells at various time 
points prior to (0 h) and following treatment with RA (3,6, 12,24, and 
72 h). Northern blot analysis was performed using a j2P-labeled cDNA 
probe to the human hsp28 gene. To verify that equal amounts of RNA 
(5 pug) were loaded at each time point, the blot was rehybridized with 
a /I-actin cDNA probe. 
we sought to determine how RA affected hsp28 protein 
expression during granulocytic differentiation of HL-60 
cells. In the present study, we demonstrate that hsp28 
protein is transiently upregulated by RA, concomitant 
with the onset of Gl cell cycle arrest. In contrast to other 
differentiating agents, hsp28 protein and mRNA are dis- 
cordantly regulated by RA. This suggests that RA-in- 
duced changes in hsp28 protein are regulated at the post- 
transcriptional level. In addition to quantitative changes 
in hsp28 protein expression, there are also rapid changes 
in hsp28 phosphorylation state. These observations im- 
plicate this hsp as an intermediary in the retinoic acid 
differentiative pathway. 
Phosphorylation of hsp28 is an important modifica- 
tion in response to a number of different stimuli. For 
example, increased hsp28 phosphorylation is one of the 
most rapid and pronounced of the cellular responses to 
heat shock. In addition, non-heat shock stimuli such as 
tumor necrosis factor, interleukin-1, and phorbol ester 
also increase hsp28 phosphorylation [23-271. Interest- 
ingly, most of these have significant effects on cell growth 
suggesting that changes in phosphorylation state are 
likely to be important in understanding the role of hsp28 
in growth-regulation. We now demonstrate that RA also 
modulates hs28 phosphorylation. A transient increased 
phosphorylation was observed, followed by a de- 
phosphorylation of the protein 45 h after RA addition. 
This is particularly intriguing in light of the recent obser- 
vation that small hsps are protein chaperones [28]. As 
such, chaperone/hsp hysically associate with and often 
modify the activity of other proteins. Formation of these 
complexes can have profound effects on cell growth 
when the associated protein is itself a growth-regulatory 
molecule [29]. For example, in adenovirus-transformed 
baby rat kidney (BRK) cells the presence of an hsp27-22 
kDa protein complex correlates inversely with the onco- 
genicity of transformed BRK cells [30]. Since changes in 
the phosphorylation state of the prokaryotic hsp GroEL 
regulate its association with other proteins [31], it is 
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likely that phosphorylation may also affect the interac- 
tion of hsp28 with associated proteins, such as growth- 
regulatory molecules. 
In addition to being a molecular chaperone, hsp28 has 
also been shown to inhibit actin polymerization by acting 
as an actin capping protein [32]. Although it is now 
known how the interaction between hsp28 and actin is 
regulated, it is interesting to speculate as to how changes 
in hsp28 phosphorylation state might affect its interac- 
tion with actin. Considering actin polymerization is es- 
sential for cell growth, inhibition of this process by hsp28 
would have profound effects on growth regulation. 
Finally, the discordant regulation of hsp28 protein 
and mRNA in response to RA is particularly intriguing 
in light of the involvement of serine proteases in RA- 
induced differentiation of leukemic cells. Proteinase 3 
(PR3) or myeloblastin is a serine protease whose down- 
regulation by RA is directly involved in initiating growth 
arrest and terminal differentiation of promyelocytic leu- 
kemic cells [33]. Virtually nothing is known about the 
substrates of PR3, which are likely to be effector mole- 
cules in the RA-differentiative pathway. We are cur- 
rently investigating whether hsp28 is a substrate for PR3 
which would suggest hat increased hsp28 protein in re- 
sponse to RA might be mediated through changes in 
protein stabilization. 
Recently, the role of the mammalian small hsp in 
growth regulation was directly demonstrated in a murine 
tumor model where its overexpression led to reduced 
growth [l l]. The consistency with which hsp28 is linked 
to growth arrest during differentiation of hematopoietic 
cells [4,5] suggests that it is likely to be functionally rele- 
vant. However, further studies will be required to dem- 
onstrate a growth-regulatory role for hsp28 during this 
process. The identification of molecules such as hsp28 
provides novel targets for the development of therapeutic 
strategies designed to overcome the maturational arrest 
characteristic of many human malignancies. 
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